Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Autozone Inc (AZO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Autozone Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Autozone Inc trades at $3,072.64 (market cap $50.16B). The key difference: Autozone Inc is the larger of the two by market cap, and Autozone Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | AZO | |
|---|---|---|
Market Cap | $39.89B | $50.16B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $4.35K |
52-Week Low | $278.09 | $2.94K |
Enterprise Value | $38.15B | $62.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
AutoZone (AZO) trades at $3,072.64, up 2.07% today, amid a bearish technical signal but strong analyst support. Recent earnings show mixed quarterly beats, with Q2 2026 results pending. Revenue has grown steadily to $18.94B in 2025, though net income margins are declining. The company continues aggressive share buybacks and international expansion, with a consensus price target of $3,740.
The outlook is cautiously optimistic, driven by buyback programs and commercial momentum, but risks include competitive pressures and margin compression. With 73% of analysts rating it a Buy, the stock offers value if execution aligns with expansion plans, though investors should monitor same-store sales trends and macroeconomic impacts on discretionary spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Autozone Inc
AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →
